AQST · Aquestive Therapeutics, Inc.
$4.65
+0.08 (+1.75%)
At close · Oct 6
Return incl. dividend (before tax)
Market Cap
$584.88M
Shares
125.51M
Volume · Oct 6
1.21M
Avg daily vol (3M)
2.64M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$4.57
Open$4.57
Day$4.46–4.61
52W close$2.95–7.49
Avg vol 30d2.4M
Short int27.2M · 21.6% float · 11.8d
Short vol50%
Last earningsAug 12, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 11
Up next
Next earnings call
Nov 8, 2026
Est · unconfirmed
· in 5 wks
filed Aug 11, 2026
call held May 14, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$54.09M
Trailing 12 months
Net income (TTM)
−$78.23M
Trailing 12 months
Revenue growth YoY
+38.1%
Year over year
Operating margin
-97.5%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-7.9%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$43.46M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+25.8%
Year over year · more shares
Price change (1Y)
-21.2%
Trailing year
Short interest
21.6%
Latest settlement · 11.8 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15.5 · calm
Equity put/call 0.59
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+5%
above
Price vs 50-day avg
−0%
below
RSI (14)
45
neutral
MACD trend
Negative
52-week position
36%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−14%
trailing
6-month return
+10%
trailing
YTD return
−29%
this year
Relative strength
−1%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $5 › 200d $4 — 50d above 200d
Institutional flow
Distributing
1 of 186 funds reported for Sep 30 · net -125 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
21.64% of float · ▲ +6.6% MoM · 11.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
186 holders — near 3-yr high, broad support
Squeeze score
84
high risk · 0–100
Fundamentals
Revenue growth
+1%
Y/Y
EPS growth
−53%
Y/Y
Free cash flow
$-53.0M
Balance sheet
$83.7M
net cash
Quant / Vol
risk profile
Volatility
77%
annualized · 1-yr
Max drawdown
−61%
past year
ATR
4.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 11, 2026
Total revenues
· 2026 Outlook
$46M – $50M
prior FY $44.55M
midpoint +7.8% Y/Y
Guided vs delivered
· last 4 settled
Total revenue
full-year 2024
guided $57M – $60M
$57.56M
In line
Total revenue
full year 2023
guided $47M – $50M
$50.58M
Beat +4.3%
Total revenues
full-year 2021
guided $47M – $49M
$50.83M
Beat +5.9%
Revenue guidance for 2020
full year 2020
guided $42M – $46M
$45.85M
In line
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+5%
Bullish
Price vs 50-day avg
−0%
Neutral
RSI (14)
45
Neutral
MACD trend
Negative
Bearish
52-week position
36%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $5 › 200d $4 — 50d above 200d
Institutional flow
Distributing
1 of 186 funds reported for Sep 30 · net -125 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
21.64% of float · ▲ +6.6% MoM · 11.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
186 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $3
Now $5 · 36%
Range high $7
vs 200-day avg +5%
vs 50-day avg 0%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cash and cash equivalents | 98.5M | Q2 2026 | — |
| Doses manufactured | 48M | second quarter 2026 | — |
| Gross Margin on total revenue | 74% | Six Months Ended June 30, 2026 | — |
| Non-GAAP adjusted costs and expenses non-GAAP | 35.23M | Six Months Ended June 30, 2026 | — |
| Non-GAAP adjusted EBITDA non-GAAP | -6.97M | Six Months Ended June 30, 2026 | — |
| Non-GAAP adjusted EBITDA excluding Non-GAAP adjusted R&D expenses non-GAAP | 624K | Six Months Ended June 30, 2026 | — |
| Non-GAAP adjusted EBITDA loss non-GAAP | $5.2M | second quarter 2026 | — |
| Non-GAAP adjusted manufacture and supply expenses non-GAAP | 7.16M | Six Months Ended June 30, 2026 | — |
| Non-GAAP adjusted R&D expenses non-GAAP | -7.59M | Six Months Ended June 30, 2026 | — |
| Non-GAAP Gross Margin on total revenue non-GAAP | 75% | Six Months Ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AQST
this stock
Aquestive Therapeutics, Inc.
|
$584.88M | -29.3% | +0.8% | — | 21.6% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$60.23B | +14.2% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$46.00B | -6.1% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$45.67B | +27.1% | +4.3% | 64.3 | 2.7% |
|
HLN
Haleon plc
|
$40.72B | -12.8% | — | — | 0.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AQST | -3.8% | -14.4% | +10.1% | -1.3% | -29.3% |
| SPY | +1.2% | +0.6% | +11.6% | +1.6% | +13.6% |
| vs SPY | -5.0% | -15.0% | -1.5% | -2.9% | -42.9% |